North America Drug-Device Combination Market is expected to grow with the CAGR of 10.9% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/north-america-drug-device-combination-market
North America drug-device combination market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in North America drug-device combination market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.
For instance:
- In September 2018, Amgen Inc. received marketing approval from the Japanese Ministry of Health, Labour and Welfare for Blincyto (blinatumomab). The first line usage of Blincyto (blinatumomab) is to treat relapsed or refractory B-cell acute lymphoblastic leukemia. This approval has accelerated company position in Japanese market.
Janssen Pharmaceuticals, Inc, (a subsidiary of Johnson & Johnson services, Inc.), is the dominating player in North America drug-device combination market. The other key players existing in the market are Mediprint, OcuMedic, Medtronic, GlaxoSmithKline Plc, BD, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Bayer AG, Micron Biomedical, Inc., Otsuka America Pharmaceutical, Inc., VAXXAS, Propeller Health, Raphas Co., Ltd., EOFLOW CO., LTD., Insulet Corporation, TheraJect, Zimmer Biomet, Amgen Inc., Eitan Medical among others.
Amgen Inc.
Amgen Inc. founded in the year 1980, headquarter in Thousand Oaks, California, United States. The Company is highly focusing on reducing the cost of healthcare and escalating its market presence. Moreover company is concentrating on R&D on novel human therapeutics for the treatment of serious illness. The company operates its business via business segment including human therapeutics which is the market focused segment. The company has several product categories which are Aimovig, Aranesp, AVSOLA, BLINCYTO, Corlanor, Repatha, Sensipar, Prolia, and Neulasta among others in which Repatha and Neulasta are the market focused categories.
For instance,
- In January 2020, Amgen Inc. announced the successful strategic collaboration with BeiGene. It is predicted that this collaboration enhanced the company’s footprints in China oncology market in the coming years.
The company has presence across North America and rest of the world. The company also has various subsidiaries including Alantos Pharmaceuticals Holdings (Delaware), Amgen Canada Inc. (Ontario), Amgen Fremont Inc. (Delaware), Amgen GmbH Germany (Germany). Amgen Ilac Ticaret Limited Sirketi (Turkey), and Amgen S.A.S. (France) among others.
Janssen Pharmaceuticals, Inc, (a subsidiary of Johnson & Johnson services, Inc.)
Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson services, Inc.), founded in 1953 headquarter is in Belgium. The company is focused on various areas of medicines such as cardiovascular & metabolism, immunology, infectious diseases & vaccines, neuroscience, oncology, and pulmonary hypertension. The company has several product categories including SmartJect, TREMFYA & SmartJect, TREMFYA are the market focused category.
For instance,
- In October 2009, Simponi (Golimumab) received European Approval as once-monthly subcutaneous anti-TNF for treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis with novel Smartject autoinjector. This has strengthened the company’s footprint in Europe and boosted the market growth.
The company has wide presence across Americas, Europe, Middle East and Africa, Asia-Pacific. The company also has various subsidiary companies including Janssen-Cilag A/S (Denmark), Janssen Pharmaceutica (Pty.) Ltd. (South Africa), Johnson & Johnson del Perú SA (Peru), Janssen-Cilag Farmacêutica Ltda. (Brazil), and Janssen Pharmaceuticals, Inc. (U.S.) among others.
GlaxoSmithKline Plc.
GlaxoSmithKline Plc founded in the year 1999, headquarter in Greater London, UK. The main focus of the company is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company operates its business via several business segments including pharmaceuticals, vaccines and consumer healthcare in which pharmaceuticals is the market focused segment. The company has several product categories which are Prescription Medicines and Vaccines, Consumer Healthcare Products and ViiV Healthcare in which Prescription Medicines and Vaccines is the market focused category.
For instance,
- In October 2020, Glaxosmithkline Plc announced that the European Medicines Agency (EMA) had accepted regulatory submissions seeking approval for the use of anti-IL5 biologic Nucala (mepolizumab) in three additional conditions: hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic granulomatosis with polyangiitis (EGPA). This has increased the company’s revenue thereby attracted more customers towards their company.
The company has a presence across North America, Europe, Asia-Pacific, South America, Middle East, and Africa. The company also has various subsidiaries, including GlaxoSmithKline Pharmaceuticals Ltd. (India), GlaxoSmithKline Pakistan (Pakistan), Tesaro (U.S.), GlaxoSmithKline LLC (Canada), and Alacer Corp. (U.S.), among others.
